Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05957159 · ClinicalTrials.gov registry record · Early Phase 1
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
A Early Phase 1 study of Alcohol Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05957159: Recruiting Early Phase 1 study of Alcohol Use Disorder, sponsored by Yale University.
NCT05957159 is a Early Phase 1 study of Alcohol Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 100 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05957159, a Early Phase 1 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately and jointly, to key clinical outcomes (e.g., craving, mood, withdrawal, time to lapse) during a quit attempt.
Primary Outcome
Time activity curves will be extracted from brain regions of interest during \[11C\]CFN PET Imaging. AUD subjects will be asked to complete this within first 6 days of abstinence. Healthy control subjects will be matched based on sex(Male/Female), smoking status (current/former/nonsmoker), and BMI (kg/m\^2)
Conditions Studied
Interventions
- OTHER Detoxification Program
- RADIATION PKAB
- RADIATION CFN
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2028-11-01 |
| Phase | Early Phase 1 |
What NCT05957159 shows while recruiting
NCT05957159 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Detoxification Program is the first listed.
NCT05957159 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05957159 about?
NCT05957159 is a clinical study titled "Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder". The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately a...
What is the current status of trial NCT05957159?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2023-11-07. Estimated completion is 2028-11-01.
What conditions does trial NCT05957159 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT05957159?
The interventions under investigation include: Detoxification Program (OTHER), PKAB (RADIATION), CFN (RADIATION).
Who is sponsoring clinical trial NCT05957159?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05957159 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05957159's enrollment target sits among peer trials
100 81st of 184 higher than 99 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impulsivity Domains and Subjective Response
RECRUITING · Early Phase 1
-
Suvorexant and Alcohol
RECRUITING · Early Phase 1
-
Anxiety During Abstinence in AUD
RECRUITING · Early Phase 1
-
Diclofenac as a KMO Inhibitor
ACTIVE NOT RECRUITING · Early Phase 1
-
Behavioral Alcohol Responses (BAR) Study
ACTIVE NOT RECRUITING · Early Phase 1
-
Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI